Navigation Links
Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine

Summary: Follow-up RAS data presented at ASCO

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gave a presentation titled "RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicates that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of other proprietary cancer peptide vaccines, including GV1001 which is in phase III clinical trials.

Hørsholm, June 4, 2007

Jakob Schmidt Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepat itis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.

http://hugin.info/131680/R/1130841/211128.pdf


'"/>




Related medicine technology :

1. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
2. Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
8. Apollo develops needle-free topical vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):